Acurx’s Groundbreaking Ibezapolstat Trial Targets Both Treatment and Prevention of Recurrent C. difficile Infection
New Clinical Trial for rCDI Launches, Aiming for Single-Agent Paradigm
Acurx Pharmaceuticals announced a novel clinical trial for ibezapolstat in patients suffering from multiply-recurrent C. difficile infection (rCDI). This trial seeks to address a major unmet need—the prevention of recurrence—in a disease affecting about 500,000 Americans annually and costing the healthcare system an estimated $5 billion each year, half of which is driven by recurring cases.
Early Results Show 96% Cure Rate and Zero Recurrence in Phase 2
In previous Phase 2 studies, ibezapolstat achieved a remarkable 96% clinical cure in 26 patients with acute CDI, with no recurrences reported after one month. Notably, all patients tracked for three months post-treatment remained infection-free. This suggests ibezapolstat may outperform current standards—vancomycin and fidaxomicin—especially for those with multiple prior recurrences, where rCDI rates can reach up to 40%.
| Treatment | Clinical Cure Rate | Sustained Cure Rate (1-Month) | Historical Recurrence Rate |
|---|---|---|---|
| Ibezapolstat (Phase 2) | 96% | 100% | 0% (Observed)* |
| Vancomycin (Historical) | 70–92% | 42–74% | 17–40% |
| Fidaxomicin (Historical) | 80–90% | 60–80% | 4–19.5% |
*No recurrences among 25 ibezapolstat-treated patients; 100% of those cured at end of treatment remained infection free at one month.
Ibezapolstat’s Unique Mechanism May Protect Microbiome and Prevent Recurrence
Ibezapolstat stands out for sparing the beneficial gut microbiome, unlike many traditional antibiotics. Recent data show that, after treatment, beneficial bacteria repopulate the gut, improving the bile acid profile—an important natural defense against C. difficile recurrence. This twin approach of eradicating infection while preserving gut health could be key to breaking the rCDI cycle.
Regulatory Momentum: Phase 3 Trials and FDA Fast-Track
With both QIDP and Fast-Track designations from the FDA and positive guidance from the EMA, Acurx is ready for Phase 3 international studies, pending funding. The company is optimistic that a successful trial could support a submission for regulatory approval as early as next year. Moreover, recent FDA updates may allow approval after a single pivotal trial, potentially fast-tracking patient access to this therapy.
What’s Next: Key Milestones and Timelines
- Open-label rCDI trial launching this month; enrollment of first patient expected in Q4.
- Up to 20 patients with at least two recurrences to enroll in initial rCDI trial.
- Results to inform a larger, controlled Phase 3 registration study.
- Extended results and trial progress to be discussed at Acurx’s March 13, 2026, earnings call.
Takeaway: Potential to Shift CDI Treatment Standards
If Phase 3 results echo the high cure and low recurrence rates observed so far, ibezapolstat could become the first single-agent therapy for both treatment and sustained prevention of rCDI—a true paradigm shift in the field. For patients and healthcare systems alike, the stakes are unusually high, and this new trial is one investors and clinicians may want to watch closely through 2026 and beyond.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI